203 related articles for article (PubMed ID: 17689649)
1. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
Callahan MB; Lachance JA; Stone RL; Kelsey J; Rice LW; Jazaeri AA
Am J Obstet Gynecol; 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PubMed ID: 17689649
[TBL] [Abstract][Full Text] [Related]
2. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
3. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
[TBL] [Abstract][Full Text] [Related]
4. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
Greene DP; Ferriss JS; Jazaeri AA
Cancer Chemother Pharmacol; 2010 Jul; 66(2):265-7. PubMed ID: 19844714
[TBL] [Abstract][Full Text] [Related]
6. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
7. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
9. Successful carboplatin desensitization in patients with proven carboplatin allergy.
Confino-Cohen R; Fishman A; Altaras M; Goldberg A
Cancer; 2005 Aug; 104(3):640-3. PubMed ID: 15977213
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
13. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
14. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
15. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
16. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
17. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
[TBL] [Abstract][Full Text] [Related]
18. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
19. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
20. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.
McAlpine JN; Kelly MG; O'malley DM; Azodi M; Coombe K; Schwartz PE; Rutherford TJ
Gynecol Oncol; 2006 Oct; 103(1):288-92. PubMed ID: 16647749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
